GlassScriptPhysician profile
Nancy G Shedd
NPI 1154376432
$5,282.04
in general payments reported to CMS, 2019-2025
36 companies · $797 in 2025
The $797 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $901 · 2020: $430 · 2021: $550 · 2022: $928 · 2023: $774 · 2024: $902 · 2025: $797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,473.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,473.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $783.31 | 2022-2025 | Vraylar, Ubrelvy, Qulipta |
| Novo Nordisk INC | $721.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $467.11 | 2019-2024 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $405.57 | 2019-2025 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $321.85 | 2019-2025 | |
| Lilly USA, LLC | $261.63 | 2019-2024 | Mounjaro, Amyvid, Emgality |
| Pfizer INC. | $256.29 | 2019-2025 | |
| Amgen INC. | $212.78 | 2019-2025 | Otezla, Repatha, Prolia |
| Baxter Healthcare | $207.90 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $205.50 | 2019-2025 | Airsupra, Farxiga |
| Idorsia Pharmaceuticals US INC | $178.88 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.48 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $109.57 | 2019-2025 | Verquvo, Gardasil 9, Capvaxive |
| Janssen Pharmaceuticals, INC | $95.47 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $90.93 | 2023-2025 | Caplyta |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Shedd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.